All In Biotech

Drug Trial Radar · NCT07784036

JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JYP0035 Capsules in Combination With Fulvestrant in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Progressed on Prior Endocrine Therapy

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Nov 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Chengdu JOYO pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JYP0035 Capsules in Combination With Fulvestrant in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Progressed on Prior Endocrine Therapy

Conditions

  • Breast Cancer

Interventions

  • JYP0035 plus FulvestrantDrug

    JYP0035 capsules 100 mg administered orally twice daily (BID). Fulvestrant 500 mg administered intramuscularly on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then on Day 1 of each subsequent 28-day cycle. One cycle is defined as 4 weeks (28 days).

  • JYP0035 placebo plus FulvestrantDrug

    JYP0035 placebo 100 mg administered orally twice daily (BID). Fulvestrant 500 mg administered intramuscularly on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then on Day 1 of each subsequent 28-day cycle. One cycle is defined as 4 weeks (28 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Tumor imaging assessments will be performed every 8 weeks (±7 days) starting from Cycle 1 Day 1 (C1D1), and every 12 weeks (±7 days) after Week 48, until radiologic disease progression, initiation of new anti-cancer t(e.g., up to approximately 24 months)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.